Potential of emodepside for vector-borne disease control

被引:0
作者
Khemrattrakool, Pattarapon [1 ]
Hongsuwong, Thitipong [1 ]
Phanphoowong, Theerawit [2 ]
Sriwichai, Patchara [2 ]
Poovorawan, Kittiyod [1 ,3 ]
Tarning, Joel [1 ,4 ]
Kobylinski, Kevin C. [1 ]
机构
[1] Mahidol Univ, Fac Trop Med, Mahidol Oxford Trop Med Res Unit, Bangkok, Thailand
[2] Mahidol Univ, Fac Trop Med, Dept Med Entomol, Bangkok, Thailand
[3] Mahidol Univ, Fac Trop Med, Dept Clin Trop Med, Bangkok, Thailand
[4] Univ Oxford, Ctr Trop Med & Global Hlth, Nuffield Dept Clin Med, Oxford, England
关键词
Emodepside; Ivermectin; Anopheles dirus; Aedes aegypti; Mosquito; Survival; NEMATODES;
D O I
10.1186/s12936-025-05250-8
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background Emodepside is an anthelmintic used in veterinary medicine that is currently under investigation in human clinical trials for the treatment of soil-transmitted helminths and possibly Onchocerca volvulus. Emodepside targets the calcium-activated voltage-gated potassium slowpoke 1 (SLO-1) channels of presynaptic nerves of pharynx and body wall muscle cells of nematodes leading to paralysis, reduced locomotion and egg laying, starvation, and death. Emodepside also has activity against Drosophila melanogaster SLO-1 channels. Orthologous SLO-1 genes are present in Anopheles gambiae and Aedes aegypti, suggesting that emodepside may have activity against mosquitoes. Methods Both Anopheles dirus and Ae. aegypti were blood-fed emodepside across a range of concentrations (1-10,000 nM) and mosquito survival was monitored for 10 days. Co-feeding experiments were also performed with An. dirus blood fed ivermectin at the concentrations that kills 25% (LC25) and 50% (LC50) of mosquitoes with and without emodepside at clinical peak concentration in humans (C-max) and five times the C-max, and mosquito survival was monitored for 10 days. Results Emodepside had weak mosquito-lethal effects in An. dirus but none observed in Ae. aegypti at the concentrations evaluated. The An. dirus emodepside LC50 was 4,623 [4,159-5,066] ng/ml which is > 100-fold greater than the peak concentrations seen in human. The ivermectin and emodepside co-feed experiment with An. dirus did not indicate any altered effect of ivermectin on mosquito survival when emodepside co-fed at human C-max or five times that of the human C-max. Conclusions Emodepside was not lethal to An. dirus at human-relevant concentrations and had no effect on Ae. aegypti survival. Thus, mass distribution of emodepside does not appear to be a potential tool for vector-borne disease control. Emodepside induced mortality in An. dirus does suggest that the SLO-1 channel could be a potential target for novel vector control and may warrant further investigation.
引用
收藏
页数:5
相关论文
共 18 条
[1]   Drug development for the treatment of onchocerciasis: Population pharmacokinetic and adverse events modeling of emodepside [J].
Assmus, Frauke ;
Hoglund, Richard M. ;
Monnot, Frederic ;
Specht, Sabine ;
Scandale, Ivan ;
Tarning, Joel .
PLOS NEGLECTED TROPICAL DISEASES, 2022, 16 (03)
[2]   Emodepside targets SLO-1 channels of Onchocerca ochengi and induces broad anthelmintic effects in a bovine model of onchocerciasis [J].
Bah, Germanus S. ;
Schneckener, Sebastian ;
Hahnel, Steffen R. ;
Bayang, Nicolas H. ;
Fieseler, Helena ;
Schmuck, Gabriele M. ;
Krebber, Ralph ;
Sarr, Anouk ;
Terjung, Carsten ;
Ngangyung, Henrietta F. ;
Ekale, David D. ;
Mfopit, Youssouf M. ;
Rufener, Lucien ;
Graham-Brown, John ;
Tanya, Vincent N. ;
Glenschek-Sieberth, Martin ;
Kulke, Daniel ;
Makepeace, Benjamin L. .
PLOS PATHOGENS, 2021, 17 (06)
[3]   Effects of the novel anthelmintic emodepside on the locomotion, egg-laying behaviour and development of Caenorhabditis elegans [J].
Bull, Kathryn ;
Cook, Alan ;
Hopper, Neil A. ;
Harder, Achim ;
Holden-Dye, Lindy ;
Walker, Robert J. .
INTERNATIONAL JOURNAL FOR PARASITOLOGY, 2007, 37 (06) :627-636
[4]   The Cyclooctadepsipeptide Anthelmintic Emodepside Differentially Modulates Nematode, Insect and Human Calcium-Activated Potassium (SLO) Channel Alpha Subunits [J].
Crisford, Anna ;
Ebbinghaus-Kintscher, Ulrich ;
Schoenhense, Eva ;
Harder, Achim ;
Raming, Klaus ;
O'Kelly, Ita ;
Ndukwe, Kelechi ;
O'Connor, Vincent ;
Walker, Robert J. ;
Holden-Dye, Lindy .
PLOS NEGLECTED TROPICAL DISEASES, 2015, 9 (10)
[5]  
Drugs for Neglected Diseases, Emodepside Phase II Trial for Treatment of Onchocerciasis (NCT05180461) ClinicalTrials.gov2022
[6]   Adverse Drug Reactions After Administration of Emodepside/Praziquantel (Profender®) in an MDR1-Mutant Australian Shepherd Dog: Case Report [J].
Gaens, Daniela ;
Leithaeuser, Carola ;
Hamann, Melanie ;
Geyer, Joachim .
FRONTIERS IN VETERINARY SCIENCE, 2019, 6
[7]   Safety, tolerability and pharmacokinetics of emodepside, a potential novel treatment for onchocerciasis (river blindness), in healthy male subjects [J].
Gillon, Jean-Yves ;
Dennison, Jeremy ;
van den Berg, Frans ;
Delhomme, Sophie ;
Dequatre Cheeseman, Karen ;
Pena Rossi, Claudia ;
Strub Wourgaft, Nathalie ;
Specht, Sabine ;
Pedrique, Belen ;
Monnot, Frederic ;
Skrabs, Susanne ;
Rodriguez, Maria-Luisa ;
Stass, Heino .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 87 (10) :3949-3960
[8]   The calcium-activated potassium channel, SLO-1, is required for the action of the novel cyclo-octadepsipeptide anthelmintic, emodepside, in Caenorhabditis elegans [J].
Guest, Marcus ;
Bull, Kathryn ;
Walker, Robert J. ;
Amliwala, Kiran ;
O'Connor, Vincent ;
Harder, Achim ;
Holden-Dye, Lindy ;
Hopper, Neil A. .
INTERNATIONAL JOURNAL FOR PARASITOLOGY, 2007, 37 (14) :1577-1588
[9]   Mechanisms of action of emodepside [J].
Harder A. ;
Holden–Dye L. ;
Walker R. ;
Wunderlich F. .
Parasitology Research, 2005, 97 (Suppl 1) :S1-S10
[10]   Evaluation of the in vitro susceptibility of various filarial nematodes to emodepside [J].
Huebner, Marc P. ;
Townson, Simon ;
Gokool, Suzanne ;
Tagboto, Senyo ;
Maclean, Mary J. ;
Verocai, Guilherme G. ;
Wolstenholme, Adrian J. ;
Frohberger, Stefan J. ;
Hoerauf, Achim ;
Specht, Sabine ;
Scandale, Ivan ;
Harder, Achim ;
Glenschek-Sieberth, Martin ;
Hahnel, Steffen R. ;
Kulke, Daniel .
INTERNATIONAL JOURNAL FOR PARASITOLOGY-DRUGS AND DRUG RESISTANCE, 2021, 17 :27-35